Cohort1: Placebo
|
Administration route |
subcutaneous injection |
Dosage |
Placebo, 1 mL, once a week for 26 weeks |
Pts |
12 |
Age |
Adult, Older_Adult |
Outcome |
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point:Mean (Standard Deviation):-2.0(8.40)|Low-density Lipoprotein Cholesterol at Baseline and the Primary Efficacy Time Point:Baseline Mean (Standard Deviation):243.7(65.6); Primary efficacy time point:236.3(52.8)|Summary of Participants With Adverse Events: |
Adverse reactions |
1/12(Cardiac disorders) |
References |
PMID:
22507979
|
|
Cohort2: mipomersen
|
Administration route |
subcutaneous injection |
Dosage |
mipomersen, 200 mg, weekly for 26 weeks |
Pts |
21 |
Age |
Adult, Older_Adult |
Outcome |
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point:Mean (Standard Deviation):-47.3(18.43)|Low-density Lipoprotein Cholesterol at Baseline and the Primary Efficacy Time Point:Baseline Mean (Standard Deviation):241.9(90.8); Primary efficacy time point:128.3(74.2)|Summary of Participants With Adverse Events: |
Adverse reactions |
No serious clinical adverse events |
References |
PMID:
22507979
|
|